Axxess Pharma, Inc. (AXXE)
Axxess Pharma, Inc. (AXXE), via wholly owned Canadian subsidiary Axxess Pharma Canada Inc., operates as a specialty health care products company offering select medicines, nutritional supplements and over-the-counter remedies. Access plans to distribute its products in the Americas as well as certain international markets where the company is negotiating licensing and distribution agreements.
The company’s 23 wholly owned prescription and non-prescription products are targeted to improve health-related conditions such as iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections and more. Axxess also aims to provide new, innovative options for areas such as high cholesterol, blood pressure, and acute pain.
Through its AllStar Health Brands, Inc. subsidiary, Axxess Pharma has received its first purchase order from Australian distributor Hardcore Beverages. The purchase order is for AllStar’s TapouT muscle recovery pain relief, muscle growth supplement and TapouT muscle post recovery supplement.
The purchase order marks AllStar's continued expansion of products into new countries, fueled by its high demand TapouT line. Hardcore Beverages and AllStar anticipate strong residual sales within the Australian beverage market, and plan to release a new product line in the fall.
AllStar has partnered with BK Racing, LLC, Cole Whitt Racing, LLC and Wide-Open Sports Marketing, Inc. in which Axxess Pharma will serve as primary sponsor of the No. 26 BK Racing NASCAR Sprint Cup Series ("NSCS") Toyota Camry. AllStar’s TapouT muscle recovery product will be fully branded on the hood, upper rear quarter panels, tv panel and below roof number.
Banjo & Matilda (BANJ)
Banjo & Matilda (BANJ) is an emerging Australian lifestyle brand recognized around the world for its signature fun sweaters and luxe cashmere basics. Inspired by a blend of Australian heritage and beach culture, the company launched its first clothing line in 2008 and continues to grow Banjo & Matilda as an international brand. The company’s cashmere sweaters are spun with natural and ethically sourced yarns from goats in the highest mountains of Inner Mongolia – each one distinguished by the brand’s hand-stitched XX logo in the right-hand corner.
Banjo & Matilda have established a long-term vision to grow distribution similarly to peers in the industry such as Vince Holding Corp. (NYSE: VNCE), which is now in more than 2,100 retail outlets; and Zadig & Voltair, which shares a similar growth pattern to the company.
Thus far, the brand is on-track to achieve this goal, amassing a rapidly growing consumer base and increasing the number of retail outlets “doors” stocking its products by 122% in a single quarter. Based on forward wholesale orders received, the company by September expects to increase the number of outlets by 433% from Q4 2013.
Banjo & Matilda is available in major and specialty retailers around the world, including Net-a-Porter, Shopbop, Harvey Nichols London, Neiman Marcus, Intermix New York, David Jones Australia and major department stores in Germany and the Middle East. Through the company’s online store, apparel is also shipped in other locations of the world, from Bondi Beach, Australia, to New Delhi, India.
Innocent, Inc. (INCT)
Innocent, Inc. (INCT) specializes in acquiring low risk, high upside oil and gas properties with substantial exploration potential. The development-stage company concentrates its efforts on North America opportunities, working closely with joint-venture partner Evergreen Petroleum to explore oil-bearing formations in Wyoming.
To minimize the risks associated with exploration, Innocent focuses on the development of proved petroleum reserves. The company’s profit strategy revolves around strategic acquisition and liquidation of selected oil and gas properties. This business plan leverages Evergreen’s ongoing geological studies to identify prospects that are worthy of acquiring oil and gas leases. Innocent’s alliance with industry experts such as Evergreen, provides the company with added extensive technical guidance and field management experience.
Through improvements in oil and gas production technologies, Innocent aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.
Innocent is backed by a management team comprised of experienced professionals with expertise in private and public enterprise, consulting, regulatory filings, journalism and communications, oil and gas, engineering, geology, drilling operations, corporate restructuring, mergers and acquisitions, debt consolidation, corporate finance, financial statement preparation and more.
Kips Bay Medical, Inc. (KIPS)
Kips Bay Medical, Inc. (KIPS) is focused on developing innovative solutions designed to advance, refine and improve cardiac surgery. More than 250,000 Americans undergo coronary artery bypass surgery (CABG) each year, making it one of the most commonly performed surgeries in the United States and creating a tremendous need for accurate and effective surgical technologies.
Targeting this market, Kips Bay has developed the eSVS Mesh, an easy-to-use metal alloy prosthesis designed to maintain patency of saphenous vein grafts used in the coronary artery bypass surgery (CABG). The eSVS Mesh is designed to fit like a sleeve on the outside of saphenous vein grafts (SVGs) to strengthen SVGs and prevent the damaging expansion of the vein graft. Kips Bay ultimately hopes to reduce or prevent the resulting injury, which can lead to SVG failure and potentially costly and complicated re-interventions for patients undergoing CABG surgery.
Kips Bay is currently conducting a feasibility trial for the U.S. FDA to demonstrate the initial safety and performance of the eSVS Mesh. Kips Bay expects to enroll up to 120 patients at 10 international and 10 U.S. sites and expects to use the data from this study as the basis for the filing of a request for an investigational device exemption to perform a larger pivotal study. The pivotal study is required to demonstrate clinical effectiveness and support a request for approval to sell the eSVS Mesh in the United States.
The eSVS Mesh has been studied in a variety of preclinical models to confirm that the device performs as expected. The company reports that these animal trials showed a statistically significant inhibition of the formation of intimal hyperplasia when the eSVS Mesh was used with an SVG in CABG procedures. Preclinical trials have been presented in peer-reviewed journals, including The Journal of Thoracic and Cardiovascular Surgery in February 2008 and the Journal of Vascular Surgery in June 2009.